<DOC>
	<DOCNO>NCT00003315</DOCNO>
	<brief_summary>RATIONALE : Drugs like liposomal amphotericin B may able relieve fungal infection side effect chemotherapy . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . It yet know whether receive liposomal amphotericin B plus sargramostim effective receive liposomal amphotericin B alone treat patient invasive fungal infection . PURPOSE : Randomized double-blinded phase III trial compare effectiveness liposomal amphotericin B without sargramostim treat patient invasive fungal infection .</brief_summary>
	<brief_title>Liposomal Amphotericin B With Without Sargramostim Treating Patients With Invasive Fungal Infection</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate benefit cytokine sargramostim ( GM-CSF ) resolve suspect proven fungal infection patient treat systemic antifungal therapy ( liposomal amphotericin B ) enter protocols MRC-LEUK-AML11 , AML12 UKALLXII . II . Assess , vitro , effect GM-CSF monocyte function cell take patient . OUTLINE : This double blind , supportive care study patient MRC-LEUK-AML11 , AML12 , UKALLXII ( successor ) . Patients stratify accord proven suspect fungal infection . Patients receive daily dos intravenous liposomal amphotericin B base stratification . All patient randomize also receive either sargramostim ( GM-CSF ) ( arm I ) placebo ( arm II ) subcutaneous injection ( intravenous infusion 4-6 hour permit subcutaneous route unacceptable ) . Treatment continue 42 day . Some patient localize lesion clinically improve consider surgical removal residual lesion . Patients may continue therapy 42 day physician 's discretion . Patients assess weekly end study ( particularly day 28 end study ) . PROJECTED ACCRUAL : There 200 patient ( 100 arm ) accrue study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients enter MRCLEUKAML11 , AML12 , UKALLXII , successor ( include undergo bone marrow transplantation part study ) proven suspect deepseated fungal infection list : Pulmonary fungal infection proven suspect Sinus infection proven suspect Fungemia proven Chronic hepatosplenic candidosis proven CT/MRI Invasive cutaneous fungal infection proven Cerebral fungal infection proven suspect PATIENT CHARACTERISTICS : Age : 15 Performance status : Karnofsky 30100 % Life expectancy : At least 6 week Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No known intolerance liposomal amphotericin B sargramostim PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 month since sargramostim Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 2 week since liposomal amphotericin B</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>infection</keyword>
</DOC>